References
- Bast R C, Jr, Feeney M, Lazarus H, Nadler L M, Colvin R B, Knapp R C. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981; 68: 1331–7
- Hanisch F G, Uhlenbruck G, Peter-Katalinic J, Egge H. Structural studies on oncofetal carbohydrate antigens (CA 19–9, CA 50 and CA 125) carried by O-linked sialyloligosaccharides on human amniotic mucins. Carbohydr Res 1988; 178: 29
- Bast R C, Jr, Klug T L, St John E, Jenison E, Niloff J M, Lazarus H, Berkowitz R S, Leavitt T, Griffiths C T, Parker L, Zurawski V R, Jr, Knapp R C. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309: 883–7
- Bast R C, Jr, Klug T L, Schaetzl E, Lavin P, Niloff J M, Greber T F, Zurawski V R, Jr, Knapp R C. Monitoring human ovarian carcinoma with a combination of CA 125, CA 19–9, and carcino-embryonic antigen. Am J Obstet Gynecol 1984; 149: 553–9
- Canney P A, Moore M, Wilkinson P M, James R D. Ovarian cancer antigen CA 125: a prospective clinical assessment of its role as a tumour marker. Br J Cancer 1984; 50: 765–9
- Kawabat S E, Bast R C, Jr, Bhan A K, Welch W R, Knapp R C, Colvin R B. Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC 125. Int J Gynecol Pathol 1983; 2: 275–85
- Klug T L, Bast R C, Jr, Niloff J M, Knapp R C, Zurawski V R, Jr. Monoclonal antibody immuno-radiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. Cancer Res 1984; 44: 1048–53
- Klapdor R, Klapdor U, Bahlo M, Dallek M, Kremer B, van Ackeren H, Schreiber H W, Greten H. CA 125 bei Karzinomen des Verdaungstraktes. Dtsch Med Wochenschr 1984; 109: 1949–54
- Ruibal A, Encabo G, Martinez-Miralles E, Murcia C, Capdevila J A, Salgado A, Martinez-Vasquez J M. CA 125 seric levels in non malignant pathologies. Bull Cancer (Paris) 1984; 71: 145–8
- Haglund C. Tumour marker antigen CA 125 in pancreatic cancer: a comparison with CA 19–9 and CEA. Br J Cancer 1986; 54: 897–901
- Del Villano B C, Brennan S, Brock P. Radio-immunometric assay for a monoclonal antibody-defined tumour marker, CA 19–9. Clin Chem 1983; 29: 549–52
- Jalanko H, Kuusela P, Roberts P, Sipponen P, Haglund C, Mäkelä O. Comparison of a new tumour marker CA 19–9°, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases. J Clin Path 1984; 37: 218–22
- Rutanen E-M, Lindgren J, Sipponen P, Stenman U-H, Saksela E, Seppälä M. Carcinoembryonic antigen in malignant and non-malignant gynecologic tumours. Circulating levels and tissue localization. Cancer 1978; 42: 581–90
- Ruoslahti E, Seppala M. Studies on carcino-fetal proteins III. Development of radioimmunoassay for alpha-fetoprotein. Demonstration of alpha-fetoprotein in serum of healthy human adults. Int J Cancer 1971; 8: 374–8
- Ashwell G, Harford J. Carbohydrate-specific receptors of the liver. Ann Rev Biochem 1982; 51: 531–54
- Bergmann J-F, Bidart J-M, George M, Beaugrand M, Levy V G, Bohoun C. Elevation of CA 125 in patients with benign and malignant ascites. Cancer 1987; 59: 213–7
- Ruoslahti E, Seppälä M. Alpha-fetoprotein in cancer and fetal development. Adv Cancer Res 1979; 29: 275–349
- Haglund C, Roberts P J, Kuusela P, Scheinin T M, Mäkelä O, Jalanko H. Evaluation of CA 19–9 as a serum tumour marker in pancreatic cancer. Br J Cancer 1986; 53: 197–202
- Omar Y T, al Baqeeb N, el Nas S A, Awwad A H, Foudeh M O, Safadi N B, Nasralla M Y, Ali M A, Szymendera J J. Serum levels of CA 125 in patients with gastrointestinal cancers. Tumour Biol 1989; 10: 316–23